CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
Integra Therapeutics has developed FiCAT, a novel gene writing platform that enhances the precision and safety of gene editing. This technology aims to treat genetic disorders and cancers by enabling the stable insertion of large DNA sequences into genomes.
Gene therapy offers a promising opportunity for treating the more than 10,000 human genetic diseases, as well as other disorders, such as cancer, by editing disease-causing genetic defects or engineering immune cells to target cancer cells.
However, most genetic disorders remain untreatable, as gene therapy still holds an untapped potential due to significant limitations of current editing technologies, that are not efficient, precise and safe enough and thus, present limitations in scope and ap…
INTEGRA THERAPEUTICS S.L.
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
Guests see up to 5 keywords.
